| | |
| Clinical data | |
|---|---|
| Trade names | Maprelin |
| Other names | Lamprey GnRH-III; H-Pyr-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH2; XHWSHDWKPG |
| Routes of administration | Injection |
| Drug class | GnRH agonist |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.223.356 |
| Chemical and physical data | |
| Formula | C59H74N18O14 |
| Molar mass | 1259.353 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Peforelin (INN ), or peforelin acetate, sold under the brand name Maprelin, is a gonadotropin-releasing hormone agonist (GnRH agonist) medication which is used in veterinary medicine in Europe and Canada. [1] [2] [3] [4] It is a GnRH analogue and a synthetic peptide, specifically a decapeptide. [1] [3] [4] The drug was introduced for veterinary use by 2001. [5]